PT-141
Also known as: Bremelanotide, Vyleesi
PT-141 (bremelanotide) is a cyclic heptapeptide melanocortin receptor agonist, specifically targeting the MC4R receptor in the central nervous system. Unlike phosphodiesterase inhibitors such as sildenafil, PT-141 works through a distinct neurological pathway to enhance sexual desire and arousal. It was FDA-approved in 2019 under the brand name Vyleesi for the treatment of hypoactive sexual desire disorder (HSDD) in perimenopausal women.
Extensive clinical evidence
Generally safe with some considerations
How It Works
PT-141 activates melanocortin-4 receptors (MC4R) in the brain, directly stimulating neural pathways involved in sexual arousal and desire.
Key Benefits
- Increases sexual desire through central nervous system pathways
- FDA-approved for hypoactive sexual desire disorder in women
- Works independently of vascular mechanisms
- On-demand dosing approximately 45 minutes before activity
- May benefit both men and women with desire-related dysfunction
Who May Benefit
- Women with hypoactive sexual desire disorder
- Men with ED not responding to PDE5 inhibitors
- Those addressing both desire and arousal
- People seeking alternatives to traditional ED medications
Dosage & Administration
Expected Timeline
Effects in 30-60 minutes lasting 24-72 hours. Used as-needed.
Safety Information
Possible Side Effects
Contraindications
Dr. Taylor's 2 Cents
“PT-141 is unique because it works on desire, not just mechanics. It's the only FDA-approved treatment for hypoactive sexual desire disorder, and it works through a completely different mechanism than Viagra or Cialis. I use it for both men and women. It's an on-demand medication.”
Discuss with Dr. Taylor →Frequently Asked Questions
How is PT-141 different from Viagra?
Is PT-141 FDA approved?
How is it administered?
What are the side effects?
Does it work for both sexes?
Published Research
An effect on the subjective sexual response in premenopausal women with sexual arousal disorder by bremelanotide (PT-141), a melanocortin receptor agonist
Diamond LE, Earle DC, Heiman JR, Rosen RC, Perelman MA, Harning R · Journal of Sexual Medicine (2006)
Key Finding: Significantly more women reported moderate or high sexual desire following bremelanotide vs placebo, with greater satisfaction in arousal among those who attempted intercourse.
Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction
Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB · International Journal of Impotence Research (2004)
Key Finding: Intranasal PT-141 induced a statistically significant erectile response vs placebo at doses above 7 mg, with onset in approximately 30 minutes and no clinically significant adverse effects.
Protocols Featuring PT-141
Want personalized guidance?
Consult with Dr. Patrick Taylor for a comprehensive evaluation and personalized protocol.
Book a ConsultationMedical Disclaimer: This information is for educational purposes only and is not medical advice. Consult a healthcare provider before starting any peptide protocol.